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Objective. Due to the localized nature of Charcot foot, systemically altered levels of inﬂammation markers can be diﬃcult to
measure. The aim of this study was to investigate whether it is possible to detect an arteriovenous (A-V) ﬂux in any locally
produced inﬂammatory biomarkers from an acute Charcot foot by comparing local and systemic measurements. Methods. We
included patients with acute diabetic Charcot foot. Blood was sampled from the vena saphena magna on the distal part of the
crus bilaterally as well as from the arteria radialis. To minimize the A-V shunting eﬀect, the feet were externally cooled with ice
water prior to resampling. Results. Both before and after cooling, the A-V ﬂux of interleukin-6 (IL-6) between the Charcot feet
and the arterial level was signiﬁcantly higher than the ﬂux between the healthy feet and the arterial level (Δvaluebefore: 7.25
versus 0.41 pg/mL, resp., p = 0 008; Δvalueafter: 10.04 versus 1.68 pg/mL, resp., p = 0 032). There were no diﬀerences in the ﬂuxes
for other markers of inﬂammation. Conclusion. We have found an increased A-V ﬂux of IL-6 in the acute diabetic Charcot foot
compared to the healthy foot in the same patients.
1. Introduction
Charcot osteoarthropathy is a rare disorder manifesting with
aseptic inﬂammation and hyperemia in and around load-
bearing bones and tissues. The process is normally unilateral
and leads to progressive, uncontrolled resorption and degen-
eration of bone mass, resulting in spontaneous fatigue bone
fractures [1–4]. While diﬀerent locations have been
described, the most common is in the feet (Charcot foot
(CF)) [5, 6], where the process can cause deformity, ulcera-
tions, and amputations. The Charcot inﬂammation can be
located at diﬀerent sites in the aﬀected foot, most promi-
nently in the midfoot [2, 7].
The precise pathological mechanisms underlying Char-
cot foot are still not fully understood. However, it is
dependent on relatively unimpaired lower limb blood
ﬂow and established peripheral neuropathy [8–11]. It can
be triggered by a number of diseases, although today
most cases occur in individuals with diabetes mellitus
[1, 2, 12].
Recent evidence suggests that the initial inﬂammation is
provoked by repeated local microtrauma and dysregulated
bone resorption [13–16], which in turn initiates the inﬂam-
matory process.
Several studies have reported changes in biomarkers
of bone resorption and inﬂammation in individuals with
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Charcot foot [17–24], and it seems that the inﬂammation
leads tomicrostructural changes in the aﬀected bones [25, 26].
Related to this, studies have explored the possible rela-
tionship between interleukin levels and acute Charcot foot
[17, 27–29] and found increased levels of interleukin-1 recep-
tor antagonist (IL-1RA), tumor necrosis factor α (TNF-α),
interleukin-6 (IL-6), and interleukin-17 subtypes A, E, and
F (IL-17A/E/F), as well as decreased levels of interleukin-1β
(IL-1β) and interleukin-8 (IL-8).
In addition, many individuals with Charcot foot also
seem to have a degree of vascular calciﬁcation and inﬂamma-
tion [30, 31]. This is of particular interest due to the connec-
tion between vascular calciﬁcation, neuropathy, and the
nuclear factor-κB (NF-κB) system, as described by Petrova
and Shanahan [32]. A possible way to assess this could be
through the system of advanced glycation end products
(AGEs) and their soluble receptors (sRAGE) [33–35].
However, the biomarkers in question might only be
produced locally around the inﬂamed bones in the foot,
which means that the signal on a systemic level can be diﬃ-
cult to register. Furthermore, a general systemic release of
these biomarkers might happen in response to a number of
inﬂammatory processes unrelated to the Charcot foot.
Therefore, it is plausible that a stronger and more speciﬁc
signal from an acute Charcot foot might be achieved by mea-
suring the ﬂux of a speciﬁc marker between the local venous
concentration in the foot and the arterial concentration.
Local sampling from the dorsal venous arch of the foot in
acute Charcot feet has previously been done by Gough et al.
and Pearson et al. [21, 23], although neither measured all
the markers discussed here. To our knowledge, local ﬂuxes
of inﬂammatory biomarkers across an acute Charcot foot
have not been measured previously.
The aim of this study was to investigate whether it is pos-
sible to detect a ﬂux in any locally produced biomarkers
from an acute Charcot foot by measuring the arteriovenous
(A-V) diﬀerence.
2. Materials and Methods
2.1. Participants. We included participants with acute
Charcot foot, recruited at the Copenhagen Wound Healing
Center at BispebjergHospital, Denmark, and at the StenoDia-
betes Center, Gentofte, Denmark. The participants were
referred by specialists after thorough physical examination,
full blood panel, X-ray, bone scintigraphy, and/or MRI. All
participantswere examined as close as possible to the reported
outbreak of the acute Charcot symptom (<3 months).
Exclusion criteria included no diabetes mellitus, temper-
ature diﬀerence< 2°C between the feet, duration> 3 months,
foot ulcers, prior foot surgery, new objective foot deformities,
bilateral Charcot foot, infection in the foot, antiosteoporotic
medication, arterial insuﬃciency, or foot or toe amputation
on either side.
To conﬁrm that the Charcot foot still had a high activity
on the day of examination as assessed by a locally elevated
blood ﬂow, this was measured in the feet with venous occlu-
sion plethysmography [36]. Foot temperature and foot
somatosensoric neuropathy as assessed by biothesiometry
were measured on the study day as well.
The study was approved by the Regional Ethical Com-
mittee for Copenhagen.
2.2. Arteriovenous Flux. To measure the ﬂuxes in biomarker
production in the acute Charcot foot, blood was sampled
from the vena saphena magna on the distal part of the
crus above the ankle. This was done on both the aﬀected
(Charcot) side and the healthy side. Arterial blood was
sampled from the a. radialis (or from the a. brachialis if
the a. radialis was inaccessible).
The venous drainage of the foot happens primarily
through the veins saphena magna and parva, while the deep
veins only play a minor role. The saphena veins connect
through the dorsal venous arch on the dorsal side of the foot.
The dorsal venous arch collects blood from both superﬁcial
and deep veins in the foot, as well as from the networks rete
venosus plantare and rete venosus dorsale pedis. The super-
ﬁcial and deep veins of the foot are linked by communicating
perforant veins. The few valves present in these perforants
are turned so that blood can only run from the deep to the
superﬁcial veins, thus helping with thermoregulation and
pressure absorption. This means that parts of the drainage
of the deep foot happen through the superﬁcial veins,
which can thus be sampled from a superﬁcial vein on the
lower leg [37–39].
A portion of the blood ﬂow in the feet bypasses normal
microcirculatory exchange by shunting directly through
A-V anastomoses. This is in part a thermoregulatory eﬀect
and is thus more prevalent at higher skin temperatures [40].
As the shunted blood will not be exposed to any biomarkers
produced in the deep foot tissue, this A-V shunting in eﬀect
dilutes the signal of any inﬂammatory biomarkers in a mixed
venous sample. To minimize this shunting eﬀect in our setup,
we cooled down the feet externally with cold water prior to
the ﬁnal sampling (tice).
2.3. Experimental Setup.All three sites were sampled simulta-
neously (tstart) (Figure 1). Fluxes between the arterial and
venous concentrations were calculated as vein − artery to
get a positive gradient if the Charcot foot produced the bio-
marker in question. After sampling, both feet were cooled
down for approximately 10 minutes in an icy water bath,
while foot temperature was measured. The three sites were
then sampled again while the participants kept their feet in
the water (tice).
In the following, venous samples from the acute Charcot
foot are denoted as CF(v) and venous samples from the non-
Charcot foot are denoted as non-CF(v).
The blood samples were centrifuged at 4°C and stored
at −80°C. All samples were analyzed together at the end of
the study.
2.4. Biomarkers. To estimate the existing interleukin proﬁle
and the highest relative concentrations, tstart samples were
analyzed on a Bio-Plex System multiplex immunoassay
screening panel (Bio-Rad Laboratories Inc., 4000 Alfred
Nobel Drive, Hercules, California 94547, USA). The panel
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used screened for IL-1β, IL-1RA, IL-6, IL-8, IL-17A, and
TNF-α, with the best signals detected for IL-6 and IL-8.
All analyses were performed by Biolab, Department
of Clinical Biochemistry, Rigshospitalet, University of
Copenhagen, Denmark. Special ELISA setups were used for
IL-6, IL-8, free soluble receptor activator of nuclear factor
kappa-Β ligand (fsRANK-L), osteoprotegerin (OPG), IL-17F,
sRAGE, and AGEs. The remaining samples were analyzed as
part of the daily hospital sample routines. The accepted
intraindividual sample CV for all assays was 20%.
(i) AGEs were measured with a Human sandwich
ELISA AGE kit (Nordic BioSite AB, Propellervägen
4A, 183 62 Täby, Sweden) (kit serial number
LS-F10641-1; range 0.78–50 ng/mL).
(ii) IL-6 was measured with an IL-6 Quantikine HS
ELISA kit (Bio-Techne Ltd., 614 McKinley Place
NE, Minneapolis, MN 55413, USA) (kit serial
number HS600B).
(iii) IL-8 was measured with a Human CXCL8 Quanti-
kine kit (Bio-Techne Ltd., 614 McKinley Place NE,
Minneapolis, MN 55413, USA) (kit serial number
D8000C).
(iv) IL-17F was measured with a Human IL-17F Plati-
num ELISA kit (AH-Diagnostics A/S, Runetoften
18, DK-8210 Aarhus V, Denmark) (kit serial
number BMS2037/2).
(v) Assays for fsRANK-L, osteoprotegerin, and sRAGE
were performed as previously described [41].
2.5. Statistical Analysis. Data are presented as mean± 1 SD or
range unless otherwise noted. An α-level of <0.05 was consid-
ered signiﬁcant. Normal distribution in data was tested using
Shapiro-Wilks tests. No transformations were used. t-tests or
paired t-tests were used for variance analysis between groups
in normally distributed data sets. For data sets not normally
distributed, nonparametric tests in the form of the Mann-
Whitney rank-sum test were used, while Wilcoxon signed-
rank tests were used for comparing paired samples.
Statistics and general data handling were done using IBM
SPSS Statistics v. 23 by IBM Corporation, SIGMAPLOT v.
11.0.0.77 by Systat Software Inc., Microsoft Excel 2000 v.
9.0.2812 by Microsoft Corporation, and Apache OpenOﬃce
4.0.1 by the Apache Software Foundation.
3. Results
3.1. Participants. We included 5 patients with acute Charcot
foot. In total, 22 patients were screened for inclusion. Of
these, 7 patients were excluded due to having foot ulcers or
receiving foot surgery and/or ulcer debridement before the
examinations. Another 7 did not want to participate or were
unable to participate due to personal reasons, while 3 patients
had had their Charcot foot for too long to be considered
acute (duration> 3 months).
The average time from the reported onset of symptoms to
examination was 7.2 weeks. The Charcot feet were on average
2.6°C warmer than the contralateral and had a 3 times
increased blood ﬂow. All 5 patients had recently started oﬀ-
loading treatment with an AirCast® removable walker boot
before measurements. All 5 patients were diagnosed with
stage 0 Charcot foot.
Anthropometric data for the participants are listed in
Table 1, along with the results for biothesiometry, venous
occlusion plethysmography, and arterial samples of markers
of bone health taken prior to the cooling of the feet (tstart).
There were a signiﬁcant higher temperature and blood ﬂow
in the acute Charcot feet compared to the healthy feet.
3.2. Multiplex Data. For IL-1β, IL-1RA, IL-17A, and TNF-α,
almost all measured values were below the multiplex limit of
detection in all samples. This was tested with both serum and
plasma. The detection limits were 1.32 pg/mL for IL-1,
29.64 pg/mL for IL-1RA, 7.99 pg/mL for IL-17A, and
12.72 pg/mL for TNF-α. There was a single signal in one
patient in IL-1RA and IL-17A (not the same patient for
both markers).
The average level of IL-6 detected was 10.6 pg/mL, and
for IL-8, it was 12.5 pg/mL.
3.3. Measurements before Cooling. Measurements from all
three sites (arterial, CF(v), and non-CF(v)) before and after
cooling are listed in Table 2. At tstart, there were no diﬀer-
ences in the levels of fsRANK-L, OPG, IL-6, IL-8, sRAGE,
or AGEs—neither between arterial and CF(v) nor between
CF(v) and non-CF(v) samples. The highest relative numeri-
cal diﬀerence was for IL-6 in arterial versus CF(v) levels
(7.31 versus 14.56) (p = 0 109). It was not possible to measure
IL-17F as it was below the assay detection limit of 7.8 pg/mL
for all samples at tstart and tice.
The venous-arterial ﬂux of IL-6 between the Charcot feet
and the arterial level was signiﬁcantly higher than the ﬂux
tstart tice
Arterial Arterial
CF(v) CF(v)non-CF(v) non-CF(v)
Ice water
Figure 1: Sites of arterial (red) or venous (blue) blood samples
before (tstart) and after (tice) external cooling of the feet. Arterial
samples were taken from the a. radialis, or from the a. brachialis if
the a. radialis was inaccessible. Venous samples were taken from a
large superﬁcial vein at the third distal part of the crus both on the
side with a Charcot foot (CF(v)) and on the side without a
Charcot foot (non-CF(v)).
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between the healthy feet and the arterial level (Δvalues: 7.25
versus 0.41 pg/mL, resp.) (p = 0 008). There were no diﬀer-
ences in fsRANK-L, OPG, IL-8, sRAGE, or AGEs.
3.4. Measurements after External Cooling. The ice bath
used for cooling maintained an average temperature of
7.7°C, and it was used for cooling for an average of
11.6min. The ice bath cooled the Charcot feet at an aver-
age of 11.0°C (from 33.7 to 22.7°C), and the non-Charcot
feet were cooled at an average of 12.9°C (from 31.1 to
18.2°C). Temperatures in each foot before and after cooling
are listed in Table 3.
At tice, there was a signiﬁcantly elevated level of IL-6
(Δvalue: 10.04 pg/mL) in the Charcot feet compared to the
arterial value (p = 0 049) (Figure 2). There was also a signiﬁ-
cantly elevated level of AGEs (Δvalue: 2.5 ng/mL) (p = 0 002)
(Table 2). There were no diﬀerences in fsRANK-L, OPG,
IL-8, or sRAGE.
The venous-arterial ﬂux for IL-6 at tice was still signiﬁ-
cantly increased in the Charcot feet (CF(v)-arterial) com-
pared to the healthy feet (non-CF(v)-arterial) (Δvalues:
10.04 versus 1.68 pg/mL) (p = 0 032). There were no dif-
ferences in the ﬂuxes for fsRANK-L, OPG, IL-8, sRAGE,
or AGEs.
The fsRANK-L/OPG ratio at tice was 3.7 in the arterial
sample, 4.0 in the CF(v) sample, and 3.8 in the non-CF(v)
sample and did not diﬀer in a one-way ANOVA on ranks
(p = 0 970).
Table 1: Anthropomorphic data for diabetes patients with acute Charcot foot (CF). Test results are from arterial sampling.
(a)
Data listed as mean; range or n
Age (years) 48.6; 26.0
Sex (m/f) 3/2
Aﬀected foot (left/right) 1/4
Diabetes type (I/II) 2/3
Diabetes duration (years) 19.2; 31.0
HbA1c (mmol/mol) (31–44mmol/mol) 73; 53
Ca2+(free, ionized) (mmol/L) (1.18–1.32mmol/L) 1.24; 0.14
PTH (pmol/L) (1.6–6.9 pmol/L) 4.5; 4.3
CRP (mg/L) (<10mg/L) 9.8; 15.0
25-OH-vitamin D (nmol/L) (50–160 nmol/L) 36.7; 52.6
Alkaline phosphatase (bone speciﬁc) (μg/L) (<20 μg/L)$ 20.3; 7.3
CTX (ng/L) (<630 ng/L)$ 240; 0.5
P1NP (μg/L) (22–87 μg/L)$ 48.3; 53.8
Osteocalcin (μg/L) (9–42 μg/L) 25.3; 42.1
(b)
Charcot foot Contralateral foot Diﬀerence, p value
Foot temperature (CF/non-CF) (°C) 33.7 31.1 Δ2.6, p = 0 004∗
Biothesiometry (CF/non-CF) (V) 42 39 Δ3, p = 0 648
Plethysmography (CF/non-CF) (mL/(100 g·min)) 6.9 1.8 Δ5.1, p = 0 045∗
∗Signiﬁcant at the chosen α-level of 0.05. $Reference range listed for 50 y.o. male where ranges diﬀer with age and/or sex.
Table 2: Levels of inﬂammation markers in local venous samples in
the acute Charcot foot (CF(v)), the healthy foot (non-CF(v)), and
arterial samples from the a. radialis. Measurements listed before
(tstart) and after (tice) external cooling of both feet with ice water.
Sampling site tstart tice
fsRANK-L (pmol/L)
Arterial 0.14 ± 0.12 0.13 ± 0.11
CF(v) 0.13 ± 0.11 0.14 ± 0.11
non-CF(v) 0.13 ± 0.11 0.14 ± 0.13
OPG (pmol/L)
Arterial 6.5 ± 5.4 6.6 ± 5.1
CF(v) 6.4 ± 5.8 7.3 ± 5.9
non-CF(v) 6.3 ± 5.5 7.5 ± 6.1
IL-6 (pg/mL)
Arterial 7.31 ± 6.88 6.25 ± 5.21
CF(v) 14.56 ± 14.27 16.29 ± 11.45
non-CF(v) 7.71 ± 7.07 7.93 ± 5.70
IL-8 (pg/mL)
Arterial 15.6 ± 7.9 13.1 ± 6.3
CF(v) 13.4 ± 4.4 12.1 ± 6.3
non-CF(v) 14.5 ± 9.6 11.5 ± 4.7
sRAGE (ng/L)
Arterial 845 ± 266 860 ± 247
CF(v) 833 ± 292 878 ± 298
non-CF(v) 827 ± 252 911 ± 293
AGEs (ng/mL)
Arterial 6.2 ± 7.7 5.4 ± 7.4
CF(v) 5.7 ± 6.8 7.9 ± 7.1
non-CF(v) 5.9 ± 7.2 8.4 ± 8.4
Data listed as mean ± 1 SD. fsRANKL= free soluble receptor activator
of nuclear factor-κB; OPG= osteoprotegerin; IL-6/IL-8 = interleukin
6/interleukin 8; sRAGE = soluble receptor for advanced glycation end
products; AGEs = advanced glycation end products.
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4. Discussion
In this study, we have tested a novel approach to evaluating
the local inﬂammatory activity in an acute Charcot foot by
measuring the venous-arterial ﬂux across the Charcot foot
while lowering the possible dilution from A-V shunting by
externally cooling the foot.
The data show a diﬀerence in the venous-arterial ﬂux of
IL-6 both before and after external cooling. We also saw a
two-fold elevated level of IL-6 in the Charcot foot compared
to the arterial level after cooling, indicating a local produc-
tion of IL-6. It is interesting that both IL-6 and AGEs only
show a signiﬁcant diﬀerence between the Charcot foot and
arterial level after cooling, thus possibly indicating an eﬀect
of limiting A-V shunting in the feet before sampling.
The results are mostly in line with what other groups
have found. Divyateja et al. indicated an increased median
IL-6 level in the Charcot foot [24], while both Petrova et al.
[17] and Folestad et al. [29] have suggested increased levels
of IL-6 systemically (although Folestad et al. did not ﬁnd an
initially increased level of IL-6).
Unlike Folestad et al., we have been unable to demon-
strate high levels of IL-17F systemically in acute Charcot
patients [27]. However, they did show an initial low level of
IL-17F (corresponding to the time where we performed our
sampling), and additionally, they used high-sensitivity ECL
as opposed to the ELISA that we used.
A ﬁnding of locally increased levels of IL-6 is of particular
interest for several reasons. As a proinﬂammatory cytokine,
its presence supports the theory regarding the pathogenesis
of acute Charcot foot as put forth by, for instance, Jeﬀcoate
et al. [13]. Furthermore, IL-6 is involved in bone resorption
through osteoclastic diﬀerentiation and activation [42–45].
Thus, the ﬁnding further supports local osteoclastic hyperac-
tivation as a central element in the Charcot foot bone metab-
olism and conﬁrms the ﬁndings of IL-6 in osteoclasts in
bone samples from Charcot feet as seen by Baumhauer
et al. [46]. The source of this local production of IL-6
remains unknown.
Recently, Petrova et al. reported that OPG was elevated in
patients with Charcot foot without a corresponding elevation
in RANK-L [17] and that osteoclasts from patients with
Charcot foot can be modulated by TNF-α through RANK-L
[47]. It is important to note however that elevated OPG levels
could be associated with neuropathy in itself [48].
Ndip et al. have indicated that individuals with Charcot
foot have an increased RANK-L/OPG ratio and suggest that
this could play a role in medial vascular calciﬁcation [22].
We have also previously shown a higher RANK-L/OPG ratio
in patients with acute Charcot foot than non-Charcot dia-
betic controls [41]. In the current setup, we did not ﬁnd a dif-
ference in the venous-arterial ﬂux or a locally elevated
RANK-L/OPG ratio. However, this was not to be expected
either as both markers only circulate in very small quantities
and furthermore have half-lives suﬃcient to recirculate the
vascular system many times, making it diﬃcult to detect a
local diﬀerence.
Regarding the increased level of AGEs after cooling, it is
unclear whether this is an expression of a local increase in pro-
duction of AGEs due to cooling, a by-product of the Charcot
inﬂammation, or merely a random sampling variation.
Table 3: Temperature measurements on the feet of each individual patient during the study day.
Patient number
Charcot foot temperature (°C) Non-Charcot foot temperature (°C)
Before cooling (tstart) After cooling (tice) Before cooling (tstart) After cooling (tice)
1 32.0 20.0 29.7 18.0
2 33.8 25.9 31.7 18.6
3 33.7 20.2 32.3 20.6
4 34.8 21.8 31.0 17.0
5 34.4 25.7 30.7 17.0
IL
-6
 (p
g/
m
L)
25
20
15
10
5
0
ticetstart
Arterial
Charcot foot
Non-Charcot foot
Figure 2: Levels of interleukin 6 (IL-6) in arterial and local venous
samples in both feet (CF(v) and non-CF(v)) before (tstart) and
after (tice) external cooling with ice water. Bars =mean; error
bars = SEM.
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The presence of tissue-bound receptors for AGEs
(RAGE) has been associated with impaired bone matrix min-
eralization and enhanced osteoclast formation [49]. AGEs
have been linked to a negative modiﬁcation of collagen integ-
rity and fragile bones in general [50–52]. Thus, if there is
indeed an increased level of AGEs present in Charcot feet,
this might account for a further weakening of the bones. Fur-
thermore, there is a link between increased levels of RAGE
and activation of the NF-κB system and several associated
cytokines [53, 54]. As such, it shares a common pathway of
inﬂuence of osteoclastic activation with RANK-L/OPG and
by extension IL-6.
4.1. Strengths and Limitations. To our knowledge, this is the
ﬁrst time that the local venous-arterial ﬂux across an acute
Charcot foot has been studied. Furthermore, we are unaware
of other studies that have limited the local A-V shunting
eﬀect prior to measuring a Charcot foot.
The study was limited by the number of available partic-
ipants. In total, we screened 22 patients and most of these
were excluded due to foot ulcers or extended time from the
symptom onset to diagnosis. Thus, part of the recruitment
issue was the rigorous exclusion criteria needed to ensure
that any possible ﬁndings were not clouded by infections,
surgery, or prolonged Charcot inﬂammation.
Furthermore, most of the assays we have used have a
limited accuracy and substantial intraindividual variations,
and thus it was diﬃcult to register any possible diﬀerences.
These variations might be the reason why we saw an increase
in AGEs after cooling in the Charcot foot compared to the
arterial level. Unless more accurate assays are developed,
future tests in a similar setup could be performed with
multiple samples from each site and each time point to help
alleviate this issue.
5. Conclusion
In conclusion, we have found an increased venous-arterial
ﬂux of IL-6 in the acute diabetic Charcot foot compared to
the healthy foot. We also found an increased level of IL-6
and AGEs in the acute Charcot foot compared to the arterial
level after, but not before, externally cooling the feet.
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